141430-65-1 Usage
Description
E 7010, also known as ABT-751, is a tubulin polymerization inhibitor that binds to the colchicine binding site on β-tubulin. It possesses the ability to inhibit tubulin polymerization in a concentration-dependent manner and has demonstrated growth inhibition in various human tumor cell lines. E 7010 is characterized by its effectiveness in inducing tumor regression in multiple cancer models and its potential to induce tumor endothelial cell retraction and reduce tumor perfusion.
Uses
Used in Anticancer Applications:
E 7010 is used as an anticancer agent for its ability to inhibit tubulin polymerization, leading to the inhibition of tumor growth in various human tumor cell lines. It has been shown to induce tumor regression in neuroblastoma, rhabdomyosarcoma, and Wilms mouse xenograft models. Additionally, E 7010 demonstrates the potential to induce tumor endothelial cell retraction and reduce tumor perfusion, making it a promising candidate for cancer treatment.
Used in Pharmaceutical Research:
E 7010 is used as a research tool for studying the effects of tubulin polymerization inhibition on cancer cell growth and the underlying mechanisms involved in tumor regression. Its ability to inhibit growth in multiple cancer cell lines and induce tumor endothelial cell retraction makes it a valuable compound for understanding the role of tubulin polymerization in cancer progression and the development of novel therapeutic strategies.
Used in Drug Development:
E 7010 is used as a lead compound in the development of new antitubulin drugs for cancer treatment. Its potent inhibition of tubulin polymerization and demonstrated efficacy in various cancer models make it a promising starting point for the design and synthesis of new drugs targeting this important cellular process.
Used in Preclinical Cancer Models:
E 7010 is used as a test compound in preclinical cancer models to evaluate its potential as a therapeutic agent for various types of cancer. Its ability to induce tumor regression in multiple cancer models and its effects on tumor endothelial cells and perfusion make it a valuable tool for assessing the efficacy and safety of new cancer treatments before they proceed to clinical trials.
Check Digit Verification of cas no
The CAS Registry Mumber 141430-65-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,1,4,3 and 0 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 141430-65:
(8*1)+(7*4)+(6*1)+(5*4)+(4*3)+(3*0)+(2*6)+(1*5)=91
91 % 10 = 1
So 141430-65-1 is a valid CAS Registry Number.
InChI:InChI=1/C18H17N3O4S/c1-25-15-8-10-16(11-9-15)26(23,24)21-17-3-2-12-19-18(17)20-13-4-6-14(22)7-5-13/h2-12,21-22H,1H3,(H,19,20)
141430-65-1Relevant articles and documents
N-((2Z)-2-((4-HYDROXYPHENYL)IMINO)-1,2-DIHYDRO-3-PYRIDINYL)-4-METHOXYBENZENESULFONAMIDE CRYSTALLINE FORM 2
-
Page/Page column 14-15, (2008/06/13)
N-((2Z)-2-((4-Hydroxyphenyl)imino)-1,2-dihydro-3-pyridinyl)-4-methoxybenzenesulfonamide Crystalline Form 2, ways to make it, compositions containing it and methods of treatment of diseases using it are disclosed.
Amorphous N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide
-
Page/Page column 2, (2008/06/13)
An amorphous drug, processes for making it, compositions containing it and methods of treatment of diseases using it are disclosed.
Novel Sulfonamides as Potential, Systemically Active Antitumor Agents
Yoshino, Hiroshi,Ueda, Norihiro,Niijima, Jun,Sugumi, Hiroyuki,Kotake, Yoshihiko,et al.
, p. 2496 - 2497 (2007/10/02)
-
